Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer

To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.

Gespeichert in:

Autor*in:	Iacovelli, Roberto [verfasserIn] Cossu Rocca, Maria Galli, Luca De Giorgi, Ugo Sabbatini, Roberto Santoni, Matteo Mosca, Alessandra Fornarini, Giuseppe Massari, Francesco Masini, Cristina Bersanelli, Melissa Biasco, Elisa Lolli, Cristian Guida, Annalisa Berardi, Rossana Terrone, Carlo Pastorino, Alessandro Ardizzoni, Andrea Pinto, Carmine Buti, Sebastiano Nolè, Franco Tortora, Giampaolo

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017

Schlagwörter:	Sunitinib Toxicity mRCC First-line Second-line Survival Pazopanib Dose reduction

Umfang:	48697

Übergeordnetes Werk:	Enthalten in: BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex - Siero, Jeroen C.W. ELSEVIER, 2014transfer abstract, Amsterdam [u.a.]
Übergeordnetes Werk:	volume:35 ; year:2017 ; number:9 ; pages:5417-54113 ; extent:48697

Links:	Volltext

DOI / URN:	10.1016/j.urolonc.2017.05.007

Katalog-ID:	ELV030716446

Internformat


LEADER	01000caa a22002652 4500
001	ELV030716446
003	DE-627
005	20230623205911.0
007	cr uuu---uuuuu
008	180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.urolonc.2017.05.007 \|2 doi
028	5	2	\|a GBVA2017018000029.pica
035			\|a (DE-627)ELV030716446
035			\|a (ELSEVIER)S1078-1439(17)30217-X
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 610 \|q VZ
100	1		\|a Iacovelli, Roberto \|e verfasserin \|4 aut
245	1	0	\|a Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
264		1	\|c 2017
300			\|a 48697
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
650		7	\|a Sunitinib \|2 Elsevier
650		7	\|a Toxicity \|2 Elsevier
650		7	\|a mRCC \|2 Elsevier
650		7	\|a First-line \|2 Elsevier
650		7	\|a Second-line \|2 Elsevier
650		7	\|a Survival \|2 Elsevier
650		7	\|a Pazopanib \|2 Elsevier
650		7	\|a Dose reduction \|2 Elsevier
700	1		\|a Cossu Rocca, Maria \|4 oth
700	1		\|a Galli, Luca \|4 oth
700	1		\|a De Giorgi, Ugo \|4 oth
700	1		\|a Sabbatini, Roberto \|4 oth
700	1		\|a Santoni, Matteo \|4 oth
700	1		\|a Mosca, Alessandra \|4 oth
700	1		\|a Fornarini, Giuseppe \|4 oth
700	1		\|a Massari, Francesco \|4 oth
700	1		\|a Masini, Cristina \|4 oth
700	1		\|a Bersanelli, Melissa \|4 oth
700	1		\|a Biasco, Elisa \|4 oth
700	1		\|a Lolli, Cristian \|4 oth
700	1		\|a Guida, Annalisa \|4 oth
700	1		\|a Berardi, Rossana \|4 oth
700	1		\|a Terrone, Carlo \|4 oth
700	1		\|a Pastorino, Alessandro \|4 oth
700	1		\|a Ardizzoni, Andrea \|4 oth
700	1		\|a Pinto, Carmine \|4 oth
700	1		\|a Buti, Sebastiano \|4 oth
700	1		\|a Nolè, Franco \|4 oth
700	1		\|a Tortora, Giampaolo \|4 oth
773	0	8	\|i Enthalten in \|n Elsevier Science \|a Siero, Jeroen C.W. ELSEVIER \|t BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex \|d 2014transfer abstract \|g Amsterdam [u.a.] \|w (DE-627)ELV012523860
773	1	8	\|g volume:35 \|g year:2017 \|g number:9 \|g pages:5417-54113 \|g extent:48697
856	4	0	\|u https://doi.org/10.1016/j.urolonc.2017.05.007 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
951			\|a AR
952			\|d 35 \|j 2017 \|e 9 \|h 5417-54113 \|g 48697 \|y 35.2017, 9, 541.e7-, (48697 S.)
953			\|2 045F \|a 610

Indexfelder

author_variant	r i ri
matchkey_str	iacovellirobertocossuroccamariagalliluca:2017----:lnclucmoptetwoeuesntnbraoaidrnfrtiera
hierarchy_sort_str	2017
publishDate	2017
allfields	10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610
spelling	10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610
allfields_unstemmed	10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610
allfieldsGer	10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610
allfieldsSound	10.1016/j.urolonc.2017.05.007 doi GBVA2017018000029.pica (DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Iacovelli, Roberto verfasserin aut Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 2017 48697 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier Cossu Rocca, Maria oth Galli, Luca oth De Giorgi, Ugo oth Sabbatini, Roberto oth Santoni, Matteo oth Mosca, Alessandra oth Fornarini, Giuseppe oth Massari, Francesco oth Masini, Cristina oth Bersanelli, Melissa oth Biasco, Elisa oth Lolli, Cristian oth Guida, Annalisa oth Berardi, Rossana oth Terrone, Carlo oth Pastorino, Alessandro oth Ardizzoni, Andrea oth Pinto, Carmine oth Buti, Sebastiano oth Nolè, Franco oth Tortora, Giampaolo oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:35 year:2017 number:9 pages:5417-54113 extent:48697 https://doi.org/10.1016/j.urolonc.2017.05.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 35 2017 9 5417-54113 48697 35.2017, 9, 541.e7-, (48697 S.) 045F 610
language	English
source	Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:35 year:2017 number:9 pages:5417-54113 extent:48697
sourceStr	Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:35 year:2017 number:9 pages:5417-54113 extent:48697
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Sunitinib Toxicity mRCC First-line Second-line Survival Pazopanib Dose reduction
dewey-raw	610
isfreeaccess_bool	false
container_title	BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex
authorswithroles_txt_mv	Iacovelli, Roberto @@aut@@ Cossu Rocca, Maria @@oth@@ Galli, Luca @@oth@@ De Giorgi, Ugo @@oth@@ Sabbatini, Roberto @@oth@@ Santoni, Matteo @@oth@@ Mosca, Alessandra @@oth@@ Fornarini, Giuseppe @@oth@@ Massari, Francesco @@oth@@ Masini, Cristina @@oth@@ Bersanelli, Melissa @@oth@@ Biasco, Elisa @@oth@@ Lolli, Cristian @@oth@@ Guida, Annalisa @@oth@@ Berardi, Rossana @@oth@@ Terrone, Carlo @@oth@@ Pastorino, Alessandro @@oth@@ Ardizzoni, Andrea @@oth@@ Pinto, Carmine @@oth@@ Buti, Sebastiano @@oth@@ Nolè, Franco @@oth@@ Tortora, Giampaolo @@oth@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	ELV012523860
dewey-sort	3610
id	ELV030716446
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030716446</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623205911.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017018000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030716446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30217-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">48697</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Luca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Giorgi, Ugo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fornarini, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masini, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bersanelli, Melissa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biasco, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lolli, Cristian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guida, Annalisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berardi, Rossana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terrone, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastorino, Alessandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ardizzoni, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buti, Sebastiano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolè, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tortora, Giampaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:5417-54113</subfield><subfield code="g">extent:48697</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">9</subfield><subfield code="h">5417-54113</subfield><subfield code="g">48697</subfield><subfield code="y">35.2017, 9, 541.e7-, (48697 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Iacovelli, Roberto
spellingShingle	Iacovelli, Roberto ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
authorStr	Iacovelli, Roberto
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV012523860
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 610 VZ Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction Elsevier
topic	ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction
topic_unstemmed	ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction
topic_browse	ddc 610 Elsevier Sunitinib Elsevier Toxicity Elsevier mRCC Elsevier First-line Elsevier Second-line Elsevier Survival Elsevier Pazopanib Elsevier Dose reduction
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	r m c rm rmc l g lg g u d gu gud r s rs m s ms a m am g f gf f m fm c m cm m b mb e b eb c l cl a g ag r b rb c t ct a p ap a a aa c p cp s b sb f n fn g t gt
hierarchy_parent_title	BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex
hierarchy_parent_id	ELV012523860
dewey-tens	610 - Medicine & health
hierarchy_top_title	BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV012523860
title	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
ctrlnum	(DE-627)ELV030716446 (ELSEVIER)S1078-1439(17)30217-X
title_full	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
author_sort	Iacovelli, Roberto
journal	BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex
journalStr	BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2017
contenttype_str_mv	zzz
container_start_page	5417
author_browse	Iacovelli, Roberto
container_volume	35
physical	48697
class	610 610 DE-600 610 VZ
format_se	Elektronische Aufsätze
author-letter	Iacovelli, Roberto
doi_str_mv	10.1016/j.urolonc.2017.05.007
dewey-full	610
title_sort	clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
title_auth	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
abstract	To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
abstractGer	To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
abstract_unstemmed	To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U
container_issue	9
title_short	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
url	https://doi.org/10.1016/j.urolonc.2017.05.007
remote_bool	true
author2	Cossu Rocca, Maria Galli, Luca De Giorgi, Ugo Sabbatini, Roberto Santoni, Matteo Mosca, Alessandra Fornarini, Giuseppe Massari, Francesco Masini, Cristina Bersanelli, Melissa Biasco, Elisa Lolli, Cristian Guida, Annalisa Berardi, Rossana Terrone, Carlo Pastorino, Alessandro Ardizzoni, Andrea Pinto, Carmine Buti, Sebastiano Nolè, Franco Tortora, Giampaolo
author2Str	Cossu Rocca, Maria Galli, Luca De Giorgi, Ugo Sabbatini, Roberto Santoni, Matteo Mosca, Alessandra Fornarini, Giuseppe Massari, Francesco Masini, Cristina Bersanelli, Melissa Biasco, Elisa Lolli, Cristian Guida, Annalisa Berardi, Rossana Terrone, Carlo Pastorino, Alessandro Ardizzoni, Andrea Pinto, Carmine Buti, Sebastiano Nolè, Franco Tortora, Giampaolo
ppnlink	ELV012523860
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth
doi_str	10.1016/j.urolonc.2017.05.007
up_date	2024-07-06T18:18:03.577Z
_version_	1803854684961636352
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030716446</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623205911.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.05.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017018000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030716446</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30217-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">48697</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">mRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Survival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pazopanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dose reduction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galli, Luca</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Giorgi, Ugo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sabbatini, Roberto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mosca, Alessandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fornarini, Giuseppe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Massari, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masini, Cristina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bersanelli, Melissa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Biasco, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lolli, Cristian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guida, Annalisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berardi, Rossana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terrone, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pastorino, Alessandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ardizzoni, Andrea</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pinto, Carmine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buti, Sebastiano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolè, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tortora, Giampaolo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:5417-54113</subfield><subfield code="g">extent:48697</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.05.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">9</subfield><subfield code="h">5417-54113</subfield><subfield code="g">48697</subfield><subfield code="y">35.2017, 9, 541.e7-, (48697 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.3994646

Nicht das Richtige dabei?

Schreiben Sie uns!

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?